Search company, investor...

Predict your next investment

Private Equity

Investments

10

Portfolio Exits

1

Service Providers

1

About Devonshire Investors

Devonshire Investors is a private equity firm specializing in buyouts. The firm seeks to invest in information, communications, technology, telecom and managed services, energy, human resources outsourcing, human resources technology, healthcare, building supply, transportation and hospitality, pharmaceutical, natural resources, publishing, food and agriculture, medical and life sciences, and real estate. The firm seeks to invest in United States, Europe, North Africa, and Asia.

Headquarters Location

82 Devonshire Street R7B

Boston, Massachusetts, 02109,

United States

617-563-9106

Want to inform investors similar to Devonshire Investors about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Devonshire Investors News

Beekeeper’s Naturals raises USD 14 million to expedite growth and keep creating the most influential global healthcare brand

Jun 19, 2023

15 June 2023, Los Angeles- Beekeeper’s Naturals revealed that a USD 14 million funding round, co-led by Devonshire Investors and CAVU Consumer Partners with participation from Vibrant Ventures and Muse Capital, had been completed. Devonshire Investors is a private investment business connected to FMR LLC, the parent company of Fidelity Investments. This comes after the 2020 Series B led by CAVU Consumer Partners for Beekeeper’s Naturals. This investment follows Beekeeper’s triple-digit YOY growth and retail expansion, which saw the company’s U.S. and Canadian site count rise from 5,000 to over 18,000 by 2022. The company’s quick expansion in retail and online will be supported by this cash, which will also help them build out their innovation pipeline. According to the company’s founder, Carly Stein Kremer, “Devonshire’s investment will support Beekeeper’s Naturals is taking another significant step towards revolutionizing the medicine cabinet and creating the most influential healthcare brand in the world.” “As we concentrate on retail expansion into 2024, we will continue to invest in brand marketing and product development.” With the help of a medical advisory board, goods developed by Beekeeper are still bridging the gap between healthcare and wellness. These products are founded on published research and clinical testing. Beekeeper’s Propolis Throat Spray, which has approximately 2 million bottles sold, is still a cult favorite for immune support, and celebrities like Lily Collins, Nas, and Cameron Diaz have invested in the company. “We are thrilled to be supporting Beekeeper’s Naturals as they accelerate their growth at retail and online,” said Suzanne Agnello, who oversaw the investment for Devonshire Investors. “The company’s propolis- and beehive-based medicines have a wide range of uses and are reshaping the OTC drug market. We believe there is a great chance the brand can keep growing quickly. Beekeeper’s Naturals, according to Jared Jacobs, Partner at CAVU Consumer Partners and Beekeeper’s Naturals Board member, “answers the call of modern consumers who demand cleaner, better-for-you, and effective alternatives to traditional OTC products.” We’re honored to work with Carly, Daniel, and the talented group they’ve put together to rethink the pharmacy aisle and create one of the most recognizable names in natural health and well-being. Beekeeper’s Naturals, a pioneer in the health and wellness market with products driven by propolis and supported by science, was founded by Carly Stein Kremer in 2017. The beekeeper-led team is dedicated to offering the cleanest, most effective therapies for contemporary health problems, such as chronic stress, restlessness, digestive problems, and sore throats. To ensure they are producing natural medicines that genuinely work, unlike other companies, they employ scientific rigor in their product development and commit to third-party pesticide testing. They prioritize people, plants, and propolis as a brand on a mission. We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!

Devonshire Investors Investments

10 Investments

Devonshire Investors has made 10 investments. Their latest investment was in Pivotal Commware as part of their Series D on August 8, 2023.

CBI Logo

Devonshire Investors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/17/2023

Series D

Pivotal Commware

$102M

No

4

6/16/2023

Series C

Beekeeper's Naturals

$14M

Yes

3

5/4/2021

Series D

Mainspring Energy

$95M

Yes

10

2/11/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/4/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/17/2023

6/16/2023

5/4/2021

2/11/2021

1/4/2021

Round

Series D

Series C

Series D

Series C

Series B

Company

Pivotal Commware

Beekeeper's Naturals

Mainspring Energy

Subscribe to see more

Subscribe to see more

Amount

$102M

$14M

$95M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

3

10

10

10

Devonshire Investors Portfolio Exits

1 Portfolio Exit

Devonshire Investors has 1 portfolio exit. Their latest portfolio exit was Iora Health on June 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/7/2021

Acquired

$99M

10

Date

6/7/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

10

Devonshire Investors Acquisitions

1 Acquisition

Devonshire Investors acquired 1 company. Their latest acquisition was NovoEd on October 16, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/16/2018

Series A

$99M

$2.04M

Acq - Fin

3

Date

10/16/2018

Investment Stage

Series A

Companies

Valuation

$99M

Total Funding

$2.04M

Note

Acq - Fin

Sources

3

Devonshire Investors Service Providers

1 Service Provider

Devonshire Investors has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Devonshire Investors Team

6 Team Members

Devonshire Investors has 6 team members, including current Managing Director, David Jegen.

Name

Work History

Title

Status

David Jegen

Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

David Jegen

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.